Full Year 2023 Poxel SA Earnings Call Transcript
Key Points
- Poxel SA (STU:7PO) reported strong growth in the commercialization of TWYMEEG in Japan, with sales expected to surpass significant thresholds, potentially increasing royalty rates.
- The company successfully concluded a monetization agreement with OrbiMed, securing a one-time cash payment of USD 50 million, which will help reduce debt and support strategic initiatives.
- Poxel SA has regained rights to territories outside Japan for TWYMEEG, opening opportunities for new partnerships and leveraging existing clinical data.
- The company has a clear roadmap for developing its metabolic disease pipeline, focusing on rare diseases with significant unmet needs.
- Poxel SA's financial restructuring efforts, including debt reduction and favorable restructuring terms, are expected to extend its cash runway until the end of 2025.
- Poxel SA reported a net loss of EUR 35.1 million for 2023, an increase from the previous year's loss of EUR 31.4 million.
- The company's cash and cash equivalents significantly decreased from EUR 13.1 million at the end of 2022 to EUR 2.3 million at the end of 2023.
- The financial liabilities increased to EUR 47.5 million in 2023, reflecting substantial debt obligations.
- There is uncertainty regarding the timeline for finalizing partnerships in China and other regions, which could impact future revenue streams.
- The company faces challenges in entering the US and European markets due to different regulatory requirements and existing market dynamics.
Good evening. Good evening, everyone, sorry. Welcome to this webinar focused on the presentation of Poxel's 2023 full-year results.
Before leaving the floor to Thomas Kuhn, CEO; Fanny Bosa, VP, Finance and Administration; and Tejdeep Bawa, VP Business Development, we would like to remind you that you have the possibility to ask your question to the management in writing through the question tab at the bottom right of your screen.
Thomas, the floor is yours.
Thank you, [Nicola]. Hello, everyone, and good afternoon and good evening. Thank you very much for attending the call. So we have several topics basically to cover today.
So first, we'll start with the presentation of our full-year 2023 financial results that have been just approved. And so Fanny will present that. We will then switch to and update you on the commercial dynamic for our lead product in diabetes, TWYMEEG, in Japan, which is then a good segue to, again, present you, following what we did last Monday, the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
